Immunic (NASDAQ: IMUX) is one of 578 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Immunic to similar companies based on the strength of its earnings, valuation, profitability, risk, dividends, institutional ownership and analyst recommendations.
Volatility and Risk
Immunic has a beta of 3.68, suggesting that its stock price is 268% more volatile than the S&P 500. Comparatively, Immunic’s competitors have a beta of 1.20, suggesting that their average stock price is 20% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Immunic and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Immunic currently has a consensus target price of $40.00, suggesting a potential upside of 176.63%. As a group, “Pharmaceutical preparations” companies have a potential upside of 60.05%. Given Immunic’s stronger consensus rating and higher possible upside, equities analysts clearly believe Immunic is more favorable than its competitors.
Valuation & Earnings
This table compares Immunic and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Immunic Competitors||$2.14 billion||$226.78 million||-425.87|
Immunic’s competitors have higher revenue and earnings than Immunic. Immunic is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Immunic and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
45.7% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 67.9% of Immunic shares are held by insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Immunic beats its competitors on 8 of the 13 factors compared.
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.